Chandler

Researchers are evaluating the safety and effectiveness of vamifeport in adults diagnosed with hereditary hemochromatosis related to the homeostatic iron regulator gene (HFE-HH). This phase 2, randomized, double-blind, placebo-controlled study aims to assess how vamifeport treatment impacts liver iron levels measured by magnetic resonance imaging (MRI) in these participants. Participants will receive either oral vamifeport capsules or matching placebo capsules during the study. The trial is conducted across multiple centers and uses a parallel-group design. The study specifically examines changes in liver iron concentration over a 360-day period. During the study, participants will undergo MRI scans to measure liver iron concentration at the start and end of the 360-day treatment period. Researchers will monitor safety and collect data on iron overload markers such as transferrin saturation and serum ferritin. The total involvement time for participants includes screening and the one-year treatment and assessment period.